"10.1371_journal.pone.0103498","plos one","2014-07-31T00:00:00Z","Alejandro Arenas-Pinto; Alan Winston; Wolfgang Stöhr; John Day; Rebecca Wiggins; Say Pheng Quah; Jonathan Ainsworth; Sue Fleck; David Dunn; Alex Accoroni; Nicholas I Paton; for the PIVOT Trial Team","MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, United Kingdom; Centre for Sexual Health and HIV Research, University College London, London, United Kingdom; Section of Infectious Diseases, Division of Medicine, Imperial College, St Mary’s Hospital Campus, London, United Kingdom; Department of HIV and GU Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom; Infectious Diseases, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom; Centre for Immunology and Infection, Department of Biology, University of York, York, United Kingdom; Department of GU Medicine, Royal Victoria Hospital, Belfast, United Kingdom; Infectious Diseases, North Middlesex University Hospital, London, United Kingdom; Psychology and Psychotherapy Department, The Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, United Kingdom; Yong Loo Lin School of Medicine, National University of Singapore, Singapore","Conceived and designed the experiments: AAP AW DD AA NP. Performed the experiments: AAP AW JD RW SPQ JA SF. Analyzed the data: WS DD. Contributed reagents/materials/analysis tools: SF. Wrote the paper: AAP AW WS DD AA NP.","The authors have read the journal’s policy and have the following conflicts: Dr Alejandro Arenas-Pinto has received honoraria or research grants, or been investigator, in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Pfizer, ViiV Healthcare and Janssen Cilag. Dr Alan Winston holds grants from the British Medical Research Council and the European Union (Framework 7). Has received honoraria or research grants, or been a consultant or investigator, in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Roche, Pfizer and ViiV Healthcare. Prof N Paton has received honoraria from Roche / Genentec for work on a DSMB; from AbbVie and Merck and Jansssen for speaking at meetings / attending advisory boards; and has received grant funding or donations of drugs for research studies from GSK, Gilead, Merck, Abbvie, Janssen and Pfizer. This does not alter their adherence to PLOS ONE policies on sharing data and materials. The rest of the authors have declared that no competing interests exist.","2014","07","Alejandro Arenas-Pinto","AAP",12,FALSE,5,7,2,6,TRUE,FALSE,TRUE,1,"12",TRUE
